Beximco Pharmaceuticals has become the first Bangladeshi company to export a pharmaceutical product to the Canadian market.
Olopatadine is an ophthalmic product for treating the symptoms of eye allergy.
This follows the treatment’s approval by Health Canada back in October 2016.
“Entry into the Canadian pharmaceutical market, following the successful launch of our first product in the US last year, is a significant step forward in strengthening our presence in North America,” said MD Nazmul Hassan.
He added: “The launch of our second product in North America is another validation of our strength in offering specialised generic products in a global setting.”